Litcius/Paper detail

ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer

Guanpeng Wang, Yeni Romero, Indhujah Thevarajan, Anna Żółkiewska

2022OncoImmunology10 citationsDOIOpen Access PDF

Abstract

and gene expression signature of TINs/PMN-MDSCs. Collectively, these results implicate ADAM12 in immunosuppression within the TME in TNBC.

Topics & Concepts

Triple-negative breast cancerImmune checkpointCancer researchTumor microenvironmentImmune systemMedicineImmunotherapyBreast cancerT cellCancerCancer cellImmunologyMetastasisInternal medicineImmune cells in cancerCancer Immunotherapy and BiomarkersCancer Cells and Metastasis
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer | Litcius